Business UpdateApr 30, 2026, 06:12 AM
IBRX ANKTIVA® 2025 Net Revenue $113M, +700% YoY
AI Summary
ImmunityBio, Inc. reported a transformational year in 2025 and early 2026, driven by the commercial success of ANKTIVA®. The company achieved approximately $113 million in net product revenue for ANKTIVA® in 2025, a 700% increase year-over-year, following its April 2024 FDA approval. Global expansion continued with approvals in the UK and EU, and a significant accelerated approval in China for metastatic non-small cell lung cancer. The company also announced its Annual Meeting of Stockholders for June 9, 2026, to elect directors and ratify auditors.
Key Highlights
- ANKTIVA® 2025 net product revenue reached approximately $113 million.
- ANKTIVA® unit sales grew by 750% over the prior year.
- ANKTIVA® received FDA approval in April 2024 for NMIBC.
- UK's MHRA approved ANKTIVA® in July 2025 for NMIBC.
- EC issued conditional marketing authorization for ANKTIVA® in EU in February 2026.
- SFDA granted accelerated approval for ANKTIVA® in metastatic NSCLC.
- Annual Meeting of Stockholders scheduled for June 9, 2026.
- Proposals include electing nine directors and ratifying Deloitte & Touche LLP.